The SPRI Clinical Trials management team has years of site level experience and a true understanding of all aspects of clinical research. As an SPRI client, you’ll be partnering with some of the industry’s most talented clinical research professionals — call today to put our expertise to work for you.
Nick Vatakis, MD, Chief Medical Officer
Dr. Vatakis, who has led the growth and expansion of SPRI from its inception, understands clinical research from both the site and the CRO perspective. He has more than 14 years of experience as a clinical investigator on over 200 trials and is recognized as an expert speaker on placebo response issues in CNS trials. As a senior manager, Nick ensures quality culture and smooth operations in all aspects of our company and provides medical and scientific expertise input. Additionally, he acts as the global lead of SPRI.
Amy Rigney, M Ed, President, Chief Operations Officer
Amy is a seasoned professional with more than 18 years of Infectious Disease experience, including leadership responsibilities for two approved hepatitis compounds. Her global Phase I-IV experience in small molecules and biologics at both the sponsor and CRO level provides a broad expertise to our clinical program. Ms. Rigney is responsible for the overall strategic development, implementation and oversight of global operations ensuring growth, profitability and quality deliverables. Additionally, she works closely with the leadership team at all levels to ensure standards, policies and systems are in place to provide delivery of a quality product across all functional groups.
Chuck Griffith, SPRI Chief Financial Officer
Chuck, who has been with SPRI since 2007, brings more than 30 years of finance experience to the team. Within SPRI, he works with our clients on budgeting and contract matters. Chuck has consistently shown the ability to be flexible and to recognize client needs while incorporating them into any and all agreements to the mutual satisfaction of all involved. Before joining SPRI, he handled two private equity buy-outs, numerous acquisitions and managed a company with over $80M in annual revenues.